Now Reading: Sun Pharma gets rights to sell bad cholesterol drug in ex-US markets
-
01
Sun Pharma gets rights to sell bad cholesterol drug in ex-US markets
Sun Pharma gets rights to sell bad cholesterol drug in ex-US markets
Sun Pharmaceutical Industries has signed an exclusive licensing agreement with LIB Therapeutics to commercialise and manufacture lerodalcibep, a drug for lowering LDL or bad cholesterol, in markets outside the US and China.…
Sun Pharmaceutical Industries has signed an exclusive licensing agreement with LIB Therapeutics to commercialise and manufacture lerodalcibep, a drug for lowering LDL or bad cholesterol, in markets outside the US and China. The drug is already approved in the EU under the brand name Lyrokaul and in the US as Lerochol.
The PCSK9 inhibitor market outside the US and China was worth USD 3.7 billion in the year to Q2 2026, growing at 38% annually, Sun Pharma said. Europe alone accounted for USD 2.9 billion of that. LIB Therapeutics will receive upfront and milestone payments plus royalties on sales.
Indian Opinion Analysis
Both sources report the deal as straight business news without any political slant. The story is notable for the market size Sun Pharma disclosed: USD 3.7 billion ex-US/China and growing at 38%. That figure, plus Sun Pharma taking on manufacturing and regulatory approvals, suggests the company sees this as a major growth driver. The next milestone will be regulatory filings in additional licensed territories, which Sun Pharma must pursue.
Coverage: 2 sources, 2 neutral
Sources (2): ndtvprofit.com (neutral report), thehindu.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry.
